Concerning medulloblastomas, the main molecular types already present in the 2016 WHO classification are retained: medulloblastomas with the activation of the WNT pathway, medulloblastomas with the activation of the SHH pathway (which can be either TP53-mutated or TP53-wildtype), and non-WNT/non-SHH medulloblastomas. This evidence concerns the gene SHH and medulloblastoma.